Swedish Orphan Biovitrum

15.05.2023 • News

Sweden’s Sobi Agrees Merger with CTI BioPharma

Swedish Orphan Biovitrum (Sobi) has agreed a merger with CTI BioPharma, a US biopharmaceutical company focused on blood-related cancers and rare diseases. Through a wholly owned, indirect subsidiary, Sobi plans to commence a cash tender offer that values CTI at $1.7 billion.

Top-Feature

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Evonik Operations GmbH (Hanau)

Biobased Feedstocks as a Roadmap to Defossilization

Free Expert Insights

Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.